Page 19 - TD-4-1

Tumor Discovery EpCAM-targeting cancer immunotherapies

doi: 10.1186/1471-2407-13-20 inflammatory response to MOC31PE immunotoxin after
cytoreductive surgery and hyperthermic intraperitoneal
18. Nambiar I. Analysis of serious adverse event: Writing a chemotherapy. Ann Surg Oncol. 2021;28:5252-5262.
narrative. Perspect Clin Res. 2018;9:103-106.
doi: 10.1245/s10434-021-10022-0
doi: 10.4103/picr.PICR-52-18
29. Showalter A, Limaye A, Oyer JL, et al. Cytokines in
19. Alewine C, Hassan R, Pastan I. Advances in anticancer immunogenic cell death: Applications for cancer
immunotoxin therapy. Oncologist. 2015;20:176-185.
immunotherapy. Cytokine. 2017;97:123-132.
doi: 10.1634/theoncologist.2014-0358
doi: 10.1016/j.cyto.2017.05.024
20. Di Paolo C, Willuda J, Kubetzko S, et al. A recombinant 30. Simão DC, Zarrabi KK, Mendes JL, et al. Bispecific T-Cell
immunotoxin derived from a humanized epithelial cell engagers therapies in solid tumors: Focusing on prostate
adhesion molecule-specific single-chain antibody fragment cancer. Cancers (Basel). 2023;15:1412.
has potent and selective antitumor activity. Clin Cancer Res.
2003;9:2837-2848. doi: 10.3390/cancers15051412
21. Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ. Immunotoxin 31. Heiss MM, Murawa P, Koralewski P, et al. The trifunctional
therapy of cancer. Nat Rev Cancer. 2006;6:559-565. antibody catumaxomab for the treatment of malignant ascites
due to epithelial cancer: Results of a prospective randomized
doi: 10.1038/nrc1891 phase II/III trial. Int J Cancer. 2010;127:2209-2221.
22. Kowalski M, Entwistle J, Cizeau J, et al. A phase i study of an doi: 10.1002/ijc.25423
intravesically administered immunotoxin targeting EpCAM
for the treatment of nonmuscle-invasive bladder cancer in 32. Sebastian M, Kiewe P, Schuette W, et al. Treatment of
BCG-refractory and BCG-intolerant patients. Drug Des malignant pleural effusion with the trifunctional antibody
Devel Ther. 2010;4:313-320. catumaxomab (removab) (anti-EpCAM Â anti-CD3) results
of a phase 1/2 study. J Immunother. 2009;32:195-202.
doi: 10.2147/DDDT.S14071
doi: 10.1097/CJI.0b013e318195b5bb
23. MacDonald GC, Rasamoelisolo M, Entwistle J, et al.
A phase I clinical study of VB4-845: Weekly intratumoral 33. Jäger M, Schoberth A, Ruf P, et al. Immunomonitoring
administration of an anti-EpCAM recombinant fusion results of a phase II/III study of malignant ascites patients
protein in patients with squamous cell carcinoma of the treated with the trifunctional antibody catumaxomab (Anti-
head and neck. Drug Des Devel Ther. 2009;2:105-114. EpCAM x anti-CD3). Cancer Res. 2012;72:24-32.
doi: 10.2147/dddt.s3442 doi: 10.1158/0008-5472.CAN-11-2235
24. Andersson Y, Engebraaten O, Juell S, et al. Phase I trial 34. Burges A, Wimberger P, Kümper C, et al. Effective relief
of EpCAM-targeting immunotoxin MOC31PE, alone of malignant ascites in patients with advanced ovarian
and in combination with cyclosporin. Br J Cancer. cancer by a trifunctional anti-EpCAM x anti-CD3 antibody:
2015;113:1548-1555. A phase I/II study. Clin Cancer Res. 2007;13:3899-3905.
doi: 10.1038/bjc.2015.380 doi: 10.1158/1078-0432.CCR-06-2769
25. Andersson Y, Inderberg EM, Kvalheim G, et al. Immune 35. Seeber A, Martowicz A, Spizzo G, et al. Soluble EpCAM
stimulatory effect of anti-EpCAM immunotoxin-improved levels in ascites correlate with positive cytology and
overall survival of metastatic colorectal cancer patients. Acta neutralize catumaxomab activity in vitro. BMC Cancer.
Oncol (Madr). 2020;59:404-409. 2015;15:372.
doi: 10.1186/s12885-015-1371-1.
doi: 10.1080/0284186X.2019.1704864
36. Knödler M, Körfer J, Kunzmann V, et al. Randomised
26. Billmann Thorgersen E, Asvall J, Storhaug Frøysnes I,
et al. Increased local inflammatory response to MOC31PE phase II trial to investigate catumaxomab (anti-EpCAM
× anti-CD3) for treatment of peritoneal carcinomatosis in
immunotoxin after cytoreductive surgery and hyperthermic patients with gastric cancer. Br J Cancer. 2018;119:296-302.
intraperitoneal chemotherapy. Ann Surg Oncol.
2021;28:5252-5262. doi: 10.1038/s41416-018-0150-6
doi: 10.1245/s10434-021-10022-0 37. Kebenko M, Goebeler ME, Wolf M, et al. A multicenter
phase 1 study of solitomab (MT110, AMG 110), a bispecific
27. Hassan R, Alewine C, Pastan I. New life for immunotoxin
cancer therapy. Clin Cancer Res. 2016;22:1055-1058. EpCAM/CD3 T-cell engager (BiTE®) antibody construct,
in patients with refractory solid tumors. Oncoimmunology.
doi: 10.1158/1078-0432.CCR-15-1623 2018;7:e1450710.
28. Thorgersen EB, Asvall J, Frøysnes IS, et al. Increased local doi: 10.1080/2162402X.2018.1450710

Volume 4 Issue 1 (2025) 11 doi: 10.36922/td.4926